


FIGURE 1



STRO-1
36.0%
STRO-4 (HSP-90β)
87.8%
CD146
65.8%
CD45
0.5%
CD34
0.1%
CD14
0.1%
Relative Cell Number
Fluorescence Intensity

FIGURE 2

Plasma Osteocalcin levels increased after each of 10/10 MPC injections by 2 weeks; maximal increase seen at lowest cell dose




FIGURE 3

Mean animal profiles for plasma osteocalcin levels following two single doses of MPC administered intravenously to Obese Mauritian Cynomolgous Monkeys




FIGURE 4

Percentage changes in osteocalcin levels following MPC treatment compared to baseline levels prior to treatment




FIGURE 5

Mean percentage changes in osteocalcin levels following MPC treatment compared to baseline levels prior to treatment




FIGURE 6

4/5 animals show progressive increase in plasma total alkaline phosphatase over 6 months of MPC treatment (as measured by Area Under the Curve analysis)




FIGURE 7

4/5 animals show progressive increase in plasma total alkaline phosphatase over 6 months of MPC treatment (as measured by % increase in Area Under the Curve analysis between 18-24 weeks and 0-6 weeks)




FIGURE 8

Percentage changes in total alkaline phosphatase levels following MPC treatment compared to baseline levels prior to treatment in individual animals




FIGURE 9